Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
03 2020
Historique:
received: 13 08 2019
accepted: 27 02 2020
entrez: 2 4 2020
pubmed: 2 4 2020
medline: 25 6 2020
Statut: epublish

Résumé

During August 2017-January 2018, more than 700,000 forcibly displaced Rohingyas crossed into Cox's Bazar, Bangladesh. In response to measles and diphtheria cases, first documented in September and November 2017, respectively, vaccination campaigns targeting children <15 years old were mobilized during September 2017-March 2018. However, in a rapidly evolving emergency situation, poor sanitation, malnutrition, overcrowding, and lack of access to safe water and healthcare can increase susceptibility to infectious diseases, particularly among children. We aimed to estimate population immunity to vaccine-preventable diseases (VPDs) after vaccination activities in the camps to identify any remaining immunity gaps among Rohingya children. We conducted a cross-sectional serologic and vaccination coverage survey in Nayapara Registered Refugee Camp ("Nayapara") and makeshift settlements (MSs) April 28, 2018 to May 31, 2018, among 930 children aged 6 months to 14 years. MSs are informal, self-settled areas with a population of more than 850,000, the majority of whom arrived after August 2017, whereas Nayapara is a registered camp and has better infrastructure than MSs, including provision of routine immunization services. Households were identified using simple random sampling (SRS) in Nayapara and multistage cluster sampling in MSs (because household lists were unavailable). Dried blood spots (DBSs) were collected to estimate seroprotection against measles, rubella, diphtheria, and tetanus, using Luminex multiplex bead assay (MBA). Caregiver interviews assessed vaccination campaign participation using vaccination card or recall. In Nayapara, 273 children aged 1 to 6 years participated; 46% were female and 88% were registered refugees. In MSs, 358 children aged 1 to 6 years and 299 children aged 7 to 14 years participated; 48% of all children in MSs were female, and none were registered refugees. In Nayapara, estimated seroprotection among 1- to 6-year-olds was high for measles, rubella, diphtheria, and tetanus (91%-98%; 95% confidence interval [CI] 87%-99%); children >6 years were not assessed. In MSs, measles seroprotection was similarly high among 1- to 6-year-olds and 7- to 14-year-olds (91% [95% CI 86%-94%] and 99% [95% CI 96%-100%], respectively, p < 0.001). Rubella and diphtheria seroprotection in MSs were significantly lower among 1- to 6-year-olds (84% [95% CI 79%-88%] and 63% [95% CI 56%-70%]) compared to 7- to 14-year-olds (96% [95% CI 90%-98%] and 77% [95% CI 69%-84%]) (p < 0.001). Tetanus seroprevalence was similar among 1- to 6-year-olds and 7- to 14-year-olds (76% [95% CI 69%-81%] and 84% [95% CI 77%-89%], respectively; p = 0.07). Vaccination campaign coverage was consistent with seroprotection in both camps. However, nonresponse, the main limitation of the study, may have biased the seroprotection and campaign coverage results. In this study, we observed that despite multiple vaccination campaigns, immunity gaps exist among children in MSs, particularly for diphtheria, which requires serial vaccinations to achieve maximum protection. Therefore, an additional tetanus-diphtheria campaign may be warranted in MSs to address these remaining immunity gaps. Rapid scale-up and strengthening of routine immunization services to reach children and to deliver missed doses to older children is also critically needed to close immunity gaps and prevent future outbreaks.

Sections du résumé

BACKGROUND
During August 2017-January 2018, more than 700,000 forcibly displaced Rohingyas crossed into Cox's Bazar, Bangladesh. In response to measles and diphtheria cases, first documented in September and November 2017, respectively, vaccination campaigns targeting children <15 years old were mobilized during September 2017-March 2018. However, in a rapidly evolving emergency situation, poor sanitation, malnutrition, overcrowding, and lack of access to safe water and healthcare can increase susceptibility to infectious diseases, particularly among children. We aimed to estimate population immunity to vaccine-preventable diseases (VPDs) after vaccination activities in the camps to identify any remaining immunity gaps among Rohingya children.
METHODS AND FINDINGS
We conducted a cross-sectional serologic and vaccination coverage survey in Nayapara Registered Refugee Camp ("Nayapara") and makeshift settlements (MSs) April 28, 2018 to May 31, 2018, among 930 children aged 6 months to 14 years. MSs are informal, self-settled areas with a population of more than 850,000, the majority of whom arrived after August 2017, whereas Nayapara is a registered camp and has better infrastructure than MSs, including provision of routine immunization services. Households were identified using simple random sampling (SRS) in Nayapara and multistage cluster sampling in MSs (because household lists were unavailable). Dried blood spots (DBSs) were collected to estimate seroprotection against measles, rubella, diphtheria, and tetanus, using Luminex multiplex bead assay (MBA). Caregiver interviews assessed vaccination campaign participation using vaccination card or recall. In Nayapara, 273 children aged 1 to 6 years participated; 46% were female and 88% were registered refugees. In MSs, 358 children aged 1 to 6 years and 299 children aged 7 to 14 years participated; 48% of all children in MSs were female, and none were registered refugees. In Nayapara, estimated seroprotection among 1- to 6-year-olds was high for measles, rubella, diphtheria, and tetanus (91%-98%; 95% confidence interval [CI] 87%-99%); children >6 years were not assessed. In MSs, measles seroprotection was similarly high among 1- to 6-year-olds and 7- to 14-year-olds (91% [95% CI 86%-94%] and 99% [95% CI 96%-100%], respectively, p < 0.001). Rubella and diphtheria seroprotection in MSs were significantly lower among 1- to 6-year-olds (84% [95% CI 79%-88%] and 63% [95% CI 56%-70%]) compared to 7- to 14-year-olds (96% [95% CI 90%-98%] and 77% [95% CI 69%-84%]) (p < 0.001). Tetanus seroprevalence was similar among 1- to 6-year-olds and 7- to 14-year-olds (76% [95% CI 69%-81%] and 84% [95% CI 77%-89%], respectively; p = 0.07). Vaccination campaign coverage was consistent with seroprotection in both camps. However, nonresponse, the main limitation of the study, may have biased the seroprotection and campaign coverage results.
CONCLUSIONS
In this study, we observed that despite multiple vaccination campaigns, immunity gaps exist among children in MSs, particularly for diphtheria, which requires serial vaccinations to achieve maximum protection. Therefore, an additional tetanus-diphtheria campaign may be warranted in MSs to address these remaining immunity gaps. Rapid scale-up and strengthening of routine immunization services to reach children and to deliver missed doses to older children is also critically needed to close immunity gaps and prevent future outbreaks.

Identifiants

pubmed: 32231368
doi: 10.1371/journal.pmed.1003071
pii: PMEDICINE-D-19-02956
pmc: PMC7108726
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003071

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Déclaration de conflit d'intérêts

I have read the journal's policy and the authors of this manuscript have the following competing interests: MV is Chief of Health at UNICEF Bangladesh. JMA is a Health Specialist at UNICEF Bangladesh. MH is a Health Specialist at UNICEF Bangladesh. SA is a Health Officer at UNICEF Bangladesh. AH is Regional Immunization Specialist at UNICEF Regional Office South-Asia.

Références

Clin Vaccine Immunol. 2016 Jul 05;23(7):546-54
pubmed: 27053629
Lancet. 2017 May 6;389(10081):1841-1850
pubmed: 27916235
Vaccine. 2011 Oct 26;29(46):8189-91
pubmed: 21893144
Wkly Epidemiol Rec. 1994 Mar 25;69(12):87-90
pubmed: 8003403
Vaccine. 2019 Feb 4;37(6):833-838
pubmed: 30642728

Auteurs

Leora R Feldstein (LR)

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Sarah D Bennett (SD)

Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Concepcion F Estivariz (CF)

Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Gretchen M Cooley (GM)

Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Lauren Weil (L)

Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Mallick Masum Billah (MM)

Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.

M Salim Uzzaman (MS)

Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.

Rajendra Bohara (R)

World Health Organization, Dhaka, Bangladesh.

Maya Vandenent (M)

United Nations Children's Fund, Dhaka, Bangladesh.

Jucy Merina Adhikari (JM)

United Nations Children's Fund, Dhaka, Bangladesh.

Eva Leidman (E)

Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Mainul Hasan (M)

United Nations Children's Fund, Dhaka, Bangladesh.

Saifuddin Akhtar (S)

United Nations Children's Fund, Dhaka, Bangladesh.

Andreas Hasman (A)

United Nations Children's Fund, Regional Office for South Asia, Kathmandu, Nepal.

Laura Conklin (L)

Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Daniel Ehlman (D)

Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

A Alamgir (A)

Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.

Meerjady Sabrina Flora (MS)

Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH